Furthermore, the combination of JCXH-211 and anti-PD1 antibody significantly improved the survival rate of B16F10 tumor-bearing mice compared to JCXH-211 and anti-PD1 antibody alone (60 vs 12.5 vs 0%, P < 0.05) (Fig. 6). Here, PDCD1 is linked to neoplasm.